A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistence

被引：0
|
作者：
Dignass, A. [1 ]
Gisbert, J. P. [2 ]
Bossa, F. [3 ]
Kelly, O. [4 ]
Rahman, M. [5 ]
Lobaton, T. [6 ]
Addison, J. [7 ]
机构：
[1] Goethe Univ, Agaples Markus Hosp, Dept Med 1, Frankfurt, Germany
[2] Univ Autonoma Madrid UAM, Hosp Univ La Princesa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Sanitaria Princesa IIS Princesa,Gastr, Madrid, Spain
[3] Fdn Casa Sollievo Sofferenza, Div Gastroenterol, IRCCS San Giovanni Rotondo, Puglia, Italy
[4] Connolly Hosp, Dept Gastroenterol, Dublin, Ireland
[5] Surrey & Sussex Healthcare NHS Trust, Dept Gastroenterol, Surrey, England
[6] Ghent Univ Hosp, Dept Internal Med & Pediat, Dept Gastroenterol, Ghent, Belgium
[7] Biogen Idec Ltd, Clin Res, Maidenhead, England
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P431
引用
收藏
页码：558 / 559
页数：2
相关论文
共 46 条
  • [21] BENEFIT STUDY: A PAN-EUROPEAN OBSERVATIONAL STUDY TO EVALUATE REAL-WORLD EFFECTIVENESS OF SB4 FOLLOWING TRANSITION FROM ORIGINATOR ETANERCEPT (ETN) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) OR AXIAL SPONDYLOARTHRITIS (AXSPA)
    Krueger, Klaus
    Selmi, Carlo
    Cantagrel, Alain
    Hernandez, Abad
    Freudensprung, Ulrich
    Rezk, Mourad Farouk
    Addison, Janet
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 717 - 718
  • [22] SUSTAINED EFFICACY AND COMPARABLE SAFETY AND IMMUNOGENICITY AFTER TRANSITION TO SB5 (AN ADALIMUMAB BIOSIMILAR) VS CONTINUATION OF THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULT OF PHASE III STUDY
    Weinblatt, M.
    Baranauskaite, A.
    Niebrzydowski, J.
    Dokoupilova, E.
    Zielinska, A.
    Sitek-Ziolkowska, K.
    Jaworski, J.
    Racewicz, A.
    Pileckyte, M.
    Jedrychowicz-Rosiak, K.
    Zhdan, V.
    Cheong, S. Y.
    Ghil, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 487 - 487
  • [23] Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
    Krueger, Klaus
    Selmi, Carlo
    Cantagrel, Alain
    Abad, Miguel A.
    Freudensprung, Ulrich
    Rezk, Mourad Farouk
    Addison, Janet
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [24] Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: A 48-week interim analysis of the MARS study
    Ishii, Tomonori
    Kunishige, Hideaki
    Kobayashi, Tamami
    Hayashi, Etsuko
    Komatsubara, Masaki
    Ishii, Takeo
    Alfonso-Cristancho, Rafael
    Tamaoki, Jun
    Howarth, Peter
    MODERN RHEUMATOLOGY, 2023, 34 (05) : 978 - 987
  • [25] IMPACT OF ADALIMUMAB SERUM CONCENTRATION ON EFFICACY AND ASSOCIATION BETWEEN ANTI-DRUG ANTIBODIES AND SERUM CONCENTRATION: 24 WEEK RESULTS FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Kay, J.
    Weinblatt, M.
    Keystone, E.
    Genovese, M.
    Ghil, J.
    Cheong, S. Y.
    Hong, E. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 136 - 136
  • [26] Real-world effectiveness & safety of fremanezumab in migraine: 3rd interim analysis of the pan-European PEARL study
    Ashina, M.
    Mitsikostas, D.
    Amin, F.
    Kokturk, P.
    Schankin, C.
    Sahin, G.
    Pozo-Rosich, P.
    Dorman, P.
    Nezadal, T.
    Poole, A.
    Martins, I.
    Sumelahti, M.
    Campos, V. Ramirez
    Ning, X.
    Lyras, L.
    Tassorelli, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 149 - 150
  • [27] Real-World effectiveness and safety of fremanezumab in migraine: 3rd interim analysis of the pan-european PEARL study
    Ashina, M.
    Mitsikostas, D. D.
    Amin, F. Mohammad
    Kokturk, P.
    Schankin, C. J.
    Sahin, G.
    Pozo-Rosich, P.
    Dorman, P.
    Nezadal, T.
    Poole, A. Christine
    Martins, I. Pavao
    Sumelahti, M. L.
    Campos, V. Ramirez
    Ning, X.
    Lyras, L.
    Tassorelli, C.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [28] Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study
    Le, Nha
    Vinci, Alessio
    Schober, Marvin
    Krug, Sebastian
    Javed, Muhammad A.
    Kohlmann, Thomas
    Sund, Malin
    Neesse, Albrecht
    Beyer, Georg
    DIGESTION, 2016, 94 (04) : 222 - 229
  • [29] Impact of Anti-Drug Antibodies on Efficacy and Safety up to Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Reference Adalimumab in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
    Genovese, Mark
    Weinblatt, Michael
    Keystone, Edward
    Baranauskaite, Asta
    Cheong, Soo-Yeon
    Ghil, Jeehoon
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 878 - 878
  • [30] NEDA3PLUS study: 48-week interim results on persistence, clinical and MRI outcomes in RRMS patients treated with teriflunomide in a real-world setting
    Amato, M. P.
    Sommacal, S.
    Mondino, M. M.
    Trojano, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 681 - 681
12345